Skip to content

Steve Garland

  • CEO/Founder
  • NQuiX Ltd
  • 10h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 539CitationsNumber of citations received by Steve's publications. Updated daily.

Recent publications

  • Corrigendum to "(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors" [Bioorg. Med. Chem. Lett. 15 (2005) 3402-3406]

    • Bamford M
    • Alberti M
    • Bailey N
    • et al.
    N/AReaders
    N/ACitations
  • Erratum: What is the potential of G protein-coupled receptor allosteric sites in drug design? (Future Medicinal Chemistry (2014) 6:7 (729-732))

    • Garland S
    N/AReaders
    0Citations

Professional experience

CEO/Founder

NQuiX Ltd

August 2011 - Present

Group Leader, Lead Generation

GlaxoSmithKline

December 2008 - August 2011(3 years)

Manager, 7TM Systems Modelling Group

GlaxoSmithKline

Computational Chemist

GlaxoSmithKline

RPR Research Fellow

University of Cambridge

Education

PhD

University of Cambridge

BA (Hons)

Oxford University

Co-authors (82)

  • Mohammad SEYEDABADI
  • David Gloriam

Other IDs